Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Short Interest Up 3,395.1% in April

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 2,132 shares, an increase of 3,395.1% from the March 31st total of 61 shares. Approximately 1.1% of the shares of the company are sold short. Based on an average daily volume of 8,439 shares, the short-interest ratio is presently 0.3 days.

Insiders Place Their Bets

In related news, insider Helen Louise Collins sold 5,000 shares of the stock in a transaction on Friday, April 17th. The shares were sold at an average price of $47.67, for a total transaction of $238,350.00. Following the completion of the sale, the insider owned 25,000 shares in the company, valued at $1,191,750. This represents a 16.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 50,000 shares of company stock worth $1,781,150. 37.30% of the stock is owned by corporate insiders.

Bitwise MARA Option Income Strategy ETF Price Performance

Shares of NYSEARCA:IMRA opened at $15.62 on Friday. The stock has a market cap of $2.97 million, a P/E ratio of 312.40 and a beta of 3.78. The firm has a fifty day moving average price of $14.09 and a 200 day moving average price of $19.35. Bitwise MARA Option Income Strategy ETF has a 1-year low of $11.99 and a 1-year high of $60.73.

About Bitwise MARA Option Income Strategy ETF

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.